<DOC>
	<DOCNO>NCT00515190</DOCNO>
	<brief_summary>Randomized phase II study design evaluate efficacy safety continuous S-1 plus oxaliplatin versus intermittent S-1 plus oxaliplatin first-line therapy patient recurrent and/or metastastic gastric carcinoma . Within 2 week end induction chemotherapy 6 cycle S-1 plus oxalipatin , patient n't experience progression randomize continuous S-1 plus oxaliplatin arm intermittent S-1 plus oxaliplatin arm 1:1 ratio .</brief_summary>
	<brief_title>Study Continuous Intermittent S-1 Combined With Oxaliplatin Recurrent Metastatic Gastric Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>1 . Histologically cytologically confirm gastric adenocarcinoma recurrent and/or metastatic disease 2 . Age ≥ 18 year 3 . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 4 . Measurable disease define Response Evaluation Criteria Solid Tumors ( RECIST ) nonmeasurable evaluable 5 . No prior treatment recurrent and/or metastatic disease ( prior adjuvant/neoadjuvant therapy allow least 6 month elapse completion adjuvant/neoadjuvant therapy enrolment study ; prior oxaliplatin allow ) 6 . Adequate major organ function include follow : Hematopoietic function : ANC &gt; = 1,500/mm3 , Platelet &gt; = 100,000/mm3 , Hepatic function : serum bilirubin = &lt; 1.5 x ULN , AST/ALT level = &lt; 2.5 x ULN ( = &lt; 5 x ULN liver metastasis present ) Renal function : serum creatinine = &lt; 1.5 x ULN 7 . Patients sign write informed consent study entry 1 . Lack physical integrity upper gastrointestinal tract malabsorption syndrome ( e.g . patient partial total gastrectomy enter study , jejunostomy probe ) , inability take oral medication 2 . Patients active ( significant uncontrolled ) gastrointestinal bleed 3 . Residual relevant toxicity result previous therapy ( exception alopecia ) ≥ grade 2 NCICTCAE version 3.0 4 . Prior and/or current history peripheral neuropathy grade 1 NCICTCAE version 3.0 5 . Inadequate cardiovascular function : New York Heart Association class III IV heart diseaseUnstable angina myocardial infarction within past 6 monthsHistory significant ventricular arrhythmia require medication antiarrhythmic significant conduction system abnormality 6 . Serious concurrent infection nonmalignant illness uncontrolled whose control may jeopardize complication study therapy 7 . Other malignancy within past 3 year except nonmelanomatous skin cancer carcinoma situ cervix 8 . History current brain metastasis 9 . Psychiatric disorder would preclude compliance 10 . Females positive pregnancy test ( within 7 day treatment start ) childbearing potential otherwise exclude ( postmenopausal i.e . amenorrheic least 2 year , hysterectomy oophorectomy ) 11 . Subjects reproductive potential willing use effective method contraception 12 . Lactating woman 13 . Known dihydropyrimidine dehydrogenase deficiency 14 . Patients receive concomitant treatment drug interact S1 flucytosine , phenytoin , warfarin et al . 15 . Major surgery within 4 week start study treatment , without complete recovery 16 . Radiotherapy within 4 week start study treatment ; 2 week interval allow palliative radiotherapy give bone metastatic site patient recover acute toxicity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Stomach Neoplasms</keyword>
	<keyword>Secondary</keyword>
	<keyword>Combination chemotherapy</keyword>
	<keyword>S-1</keyword>
	<keyword>oxaliplatin</keyword>
</DOC>